OverviewSuggest Edit

G1 is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of cancer. The Company focuses on cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells, and represents a recently validated and promising class of targets for anti-cancer therapeutics.
TypePublic
Founded2008
Websiteg1therapeutics.com

Latest Updates

Employees (est.) (Feb 2019)44
Job Openings5
Revenue (FY, 2017)$0
Share Price (Oct 2019)$21.4 (+4%)

Key People/Management at G1 Therapeutics

Mark Velleca

Mark Velleca

CEO
Rajesh Malik

Rajesh Malik

Chief Medical Officer
Jay Strum

Jay Strum

Chief Scientific Officer
Greg Mossinghoff

Greg Mossinghoff

Chief Business Officer
Show more

G1 Therapeutics Office Locations

G1 Therapeutics has an office in
Show all (1)

G1 Therapeutics Financials and Metrics

G1 Therapeutics Revenue

USD

Net income (FY, 2018)

(85.3m)

EBIT (FY, 2018)

(89.3m)

Market capitalization (16-Oct-2019)

804.5m

Closing stock price (16-Oct-2019)

21.4

Cash (31-Dec-2018)

369.3m
G1 Therapeutics's current market capitalization is $804.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

522.0k

Revenue growth, %

(100%)

General and administrative expense

3.2m5.2m7.1m18.6m

R&D expense

12.7m25.2m53.9m70.7m
Quarterly
USDQ3, 2017Q2, 2018

General and administrative expense

1.9m3.3m

R&D expense

14.1m18.4m

Operating expense total

15.9m21.7m

EBIT

(15.9m)(21.7m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

47.3m103.8m369.3m

Prepaid Expenses

596.0k849.0k

Current Assets

47.9m104.7m370.1m

PP&E

311.0k510.0k1.1m
Quarterly
USDQ3, 2017Q2, 2018

Cash

118.4m188.2m

Current Assets

119.0m189.9m

PP&E

516.0k711.0k

Total Assets

119.6m190.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(20.3m)(30.3m)(60.1m)(85.3m)

Depreciation and Amortization

42.0k67.0k89.0k175.0k

Accounts Payable

1.7m3.4m6.3m(1.0m)

Cash From Operating Activities

(13.8m)(25.1m)(50.5m)(74.3m)
Quarterly
USDQ3, 2017

Net Income

(43.1m)

Depreciation and Amortization

59.0k

Accounts Payable

5.0m

Cash From Operating Activities

(35.8m)
USDY, 2018

Financial Leverage

1 x
Show all financial metrics

G1 Therapeutics Online and Social Media Presence

Embed Graph

G1 Therapeutics News and Updates

G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019

-- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary results fr…

G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

-- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients receiving trilaciclib and chemotherapy in combination with Tecentriq® --

G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress

-  Company to present first clinical data on oral SERD G1T48 in breast cancer -

G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 01, 2019 (GLOBE NEWSWIRE) -- - New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients -

G1 Therapeutics stock rallies 25%; company to file application for new cancer drug

G1 Therapeutics Inc. shares skyrocketed 25% in the extended session Monday after the company said it expects to file a new-drug application for its trilaciclib, a drug designed to protect bone marrow from the effects of chemotherapy. That's based on feedback from a meeting with the U.S. Food and Dr…

G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 27, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference. The…
Show more

G1 Therapeutics Blogs

G1 Therapeutics Provides Second Quarter 2019 Corporate and Financial Update

-  FDA grants Breakthrough Therapy Designation for trilaciclib based on myelopreservation data in small cell lung cancer patients -  First clinical data on oral SERD G1T48 in breast cancer to be presented at ESMO 2019 Congress -  Management to host webcast and conference call today at 4:30 p.m.

G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August

G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August Content Import Tue, 08/06/2019 - 07:01 G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August August 6, 2019 at 7:00 AM EDT This release is a backf…

G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019

G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019 Content Import Wed, 07/31/2019 - 07:01 G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019 July 31, 2019 at 7:00 AM EDT This relea…

G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer

G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer Content Import Tue, 07/30/2019 - 07:01 G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer July 30, 2019 at 7:01 AM EDT This release is a backfill from a News Wire G…

G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting

G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting Content Import Fri, 06/14/2019 - 07:02 G1 Therapeutics to Present Patient-…

G1 Therapeutics Announces Updates to Board of Directors

G1 Therapeutics Announces Updates to Board of Directors Content Import Thu, 06/13/2019 - 07:02 G1 Therapeutics Announces Updates to Board of Directors June 13, 2019 at 7:01 AM EDT This release is a backfill from a News Wire General - …
Show more

G1 Therapeutics Frequently Asked Questions

  • When was G1 Therapeutics founded?

    G1 Therapeutics was founded in 2008.

  • Who are G1 Therapeutics key executives?

    G1 Therapeutics's key executives are Mark Velleca, Rajesh Malik and Jay Strum.

  • How many employees does G1 Therapeutics have?

    G1 Therapeutics has 44 employees.

  • Who are G1 Therapeutics competitors?

    Competitors of G1 Therapeutics include Invectys, Rich Pharmaceuticals and Alpine Immune Sciences.

  • Where are G1 Therapeutics offices?

    G1 Therapeutics has an office in.

  • How many offices does G1 Therapeutics have?

    G1 Therapeutics has 1 office.